A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

NCT04917809 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
Recurrent Bladder Cancer
FGFR3 Gene Mutation

Interventions

DRUG: Erdafitinib

Sponsor

Memorial Sloan Kettering Cancer Center